• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of clinical psychopharmacology >Rivastigmine as an effective add-on to standard treatment of veterans with chronic posttraumatic stress disorder: A case series
【24h】

Rivastigmine as an effective add-on to standard treatment of veterans with chronic posttraumatic stress disorder: A case series

机译：RIVASTIGMINE作为具有慢性故障压力障碍的退伍军人标准治疗的有效附加附加附加附加附件：案例系列

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: After 23 years of the end of the Iran-Iraq war, the country is left with many patients with chronic posttraumatic stress disorder (PTSD) who need close psychiatric services and are in need for recurrent hospitalization. So far, there are no reports of the rivastigmine use in PTSD patients. We report dramatic reduction of symptoms in 3 veterans with chronic PTSD, after rivastigmine augmentation. CASE PRESENTATION: This report describes the efficacy of rivastigmine as an add-on to standard treatment of 3 Iranian male veterans with chronic PTSD (aged 52, 46, and 45 years) with severe active symptoms in all 3 dimensions of the disorder. Although they had gone through many approved drug treatments (selective serotonin reuptake inhibitors, tricyclic antidepressants, mood stabilizers, antipsychotics, benzodiazepines, β-blockers, and so on), from the beginning of the disorder, their recovery remained poor (PTSD Checklist-Military Version [PCL-M] scores were 67, 71, and 73 before rivastigmine add-on). Rivastigmine was added to the ongoing therapeutic regimens of the patients for 6 months.Evaluating their condition with PCL-M after 1 and 6 months of treatment showed a significant improvement in patients with PTSD (PCL-M scores were 37, 40, and 47 and dropped to 30, 27, and 31, respectively). Hyperarousal symptoms of PTSD in patients are noted to be the most improved. The rivastigmine add-on experience did not report any adverse effects. CONCLUSIONS: The present study showed that rivastigmine is an effective and safe add-on to treatment of patients with chronic PTSD. This effect could be due to improved cognitive status or cholinergic-adrenergic balance adjustment in patients.
机译：背景：在伊朗 - 伊拉克战争结束后23年后，该国留下了许多患有密切精神服务的慢性创宫应激障碍（PTSD）患者，需要进行复发住院治疗。到目前为止，PTSD患者的菌敏曲线使用没有报道。在RIVASTIGMINE增强之后，我们报告了3名退伍军人的症状减少了症状。案例介绍：本报告描述了利夫利格作为慢性病患者（52名，46岁，46岁，45岁）的3伊朗男性退伍军人标准治疗的疗效。虽然他们经历了许多批准的药物治疗（选择性血清素再摄取抑制剂，三环抗抑郁药，情绪稳定剂，抗精神病药，苯并二氮杂虫，β-obleter等），从疾病开始时，他们的恢复仍然贫困（PTSD清单 - 军队版本[pcl-m]分数为67,71和73，然后rivigmine加载项前）。将RIVASTIGMINE加入到患者的正在进行的治疗方案中6个月。1至6个月后的PCL-MEVALUATING患有PTCL-M的病症表现出PTSD患者的显着改善（PCL-M分数为37,40和47分别下降到30,27和31个）。患者中应激障碍的稳定性症状最有改善。 Rivastigmine附加经验没有报告任何不利影响。结论：本研究表明，Rivastigmine是一种有效和安全的加载作用，治疗慢性病毒患者的患者。这种效果可能是由于改善了患者的认知状态或胆碱能性 - 肾上腺素能平衡调整。

著录项

  • 来源
  • 作者

    FayyaziBordbarM.R.; TalaeiA.;

  • 作者单位

    Psychiatry and Behavioral Sciences Research Center Mashhad University of Medical Sciences Mashhad;

    Psychiatry and Behavioral Sciences Research Center Mashhad University of Medical Sciences Mashhad;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号